Biopharma staffers exhausted and susceptible to burnout, report says
Fierce Pharma
MAY 24, 2023
Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Fierce Pharma
MAY 24, 2023
Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MAY 22, 2023
Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04
Fierce Pharma
MAY 25, 2023
The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21
Fierce Pharma
MAY 16, 2023
FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41
Fierce Pharma
MAY 9, 2023
Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18
Fierce Pharma
MARCH 21, 2023
Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14
Fierce Pharma
APRIL 19, 2023
Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39
Fierce Pharma
MAY 18, 2023
The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13
Fierce Pharma
MAY 9, 2023
We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56
Fierce Pharma
DECEMBER 21, 2022
Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.
Fierce Pharma
SEPTEMBER 17, 2022
AbbVie and BMS slash 360 jobs in California, the latest in a streak of biopharma layoffs. fkansteiner. Fri, 09/16/2022 - 13:34.
Fierce Pharma
DECEMBER 20, 2022
2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.
European Pharmaceutical Review
APRIL 17, 2023
A report on automation in the biopharma industr y has shown that the market is projected to grow at a compound annual growth rate (CAGR) of 5.7 Factors impacting the automation in the biopharma industry market The report found that 75 percent of pharmaceutical organisations want to use automated solutions more frequently.
MedCity News
MAY 9, 2023
Baxter International is selling its biopharma solutions business to private equity firms. The transaction is part of a broader trend in which life science firms are spinning out or selling operations in order to hone the focus of the remaining business on certain areas.
PharmaVoice
MAY 23, 2023
These genetic advances could play a part in our biopharma future. Ancient DNA from a deer tooth. A new way to connect genes with disease. Biological super-computing.
MedCity News
MAY 11, 2023
Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.
PharmaTech
JUNE 1, 2023
A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.
Pharmaceutical Technology
JUNE 2, 2023
Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.
Fierce Pharma
JANUARY 23, 2023
Call for nominations: The most influential people in biopharma in 2023 esagonowsky Mon, 01/23/2023 - 14:32
Pharmaceutical Technology
FEBRUARY 28, 2023
Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs. This can result in reductions in costs for our customers.” Download to learn more.
Pharmaceutical Technology
MAY 26, 2023
HanAll Biopharma and Daewoong Pharmaceutical have entered into a co-development deal with NurrOn Pharmaceuticals to develop therapy for Parkinson’s disease (PD) and other neurodegenerative disorders. By activating Nurr1, ATH-399A slows disease progression in PD patients.
European Pharmaceutical Review
MARCH 31, 2023
Impact of SVB UK acquisition on European biopharma companies One Netherlands-based biopharmaceutical company anticipated that the acquisition of SVP UK would allow access to its $19 million deposit and not experience losses, noted GlobalData.
Fierce Pharma
NOVEMBER 22, 2022
2023 preview: Despite Biden's drug pricing win, the biopharma industry is not 'anywhere near done with this conversation'. esagonowsky. Tue, 11/22/2022 - 14:22.
Pharmaceutical Technology
MAY 10, 2023
Swedish Orphan Biovitrum (Sobi) has entered into a definitive agreement to buy biopharmaceutical company CTI BioPharma in an all-cash deal valued at $1.7bn. Sobi will start a tender offer through its wholly owned indirect subsidiary to buy all outstanding CTI shares for $9.10 for each share of common stock in cash.
Pharma Leaders
APRIL 28, 2023
Swedish biotech company Hansa Biopharma has entered a research and development collaboration with Genethon. The partnership will assess the efficacy and safety of imlifidase, Hansa Biopharma’s antibody cleaving enzyme, in a clinical trial.
Pharmaceutical Commerce
APRIL 21, 2023
In this latest Harvard Business School Healthcare Alumni Association Q&A, Dr. Peter Cappelli, Professor of Management at The Wharton School and Director of Wharton’s Center for Human Resources, explains how biopharma C-suites can lead their teams through 2023’s turbulent times.
European Pharmaceutical Review
OCTOBER 18, 2022
A study published in Drug Discovery Today found that although outsourcing of biopharma R&D offers productivity benefits, near-term gains can be offset by slower innovation over the long term. Trends in biopharma contract manufacturing 2022. .
PharmaVoice
NOVEMBER 21, 2022
Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.
PharmaVoice
APRIL 27, 2023
Events over the last year, including Pfizer’s Seagen buy and AstraZeneca’s CinCor deal, have foreshadowed the comeback of biopharma M&A.
Pharmaceutical Technology
MARCH 22, 2023
The appeal of process intensification continues to grow in the biopharma industry as a means of not only increasing the productivity, but also improving sustainability. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield.
PharmaVoice
MAY 4, 2023
A number of biopharma companies slashed their workforces this year and as market anxieties persist, more challenges could be looming.
Pharmaceutical Technology
OCTOBER 4, 2022
The post Pfizer acquires biopharma firm Biohaven for $11.6bn appeared first on Pharmaceutical Technology. “Combined with Pfizer’s global reach, this acquisition increases our potential to bring new treatment options to patients with migraine – a disease which affects over one billion people worldwide.”.
MedCity News
NOVEMBER 14, 2022
These platforms need to replace traditional data management methods and workflows for biopharma companies and contract development and manufacturing organizations that seek competitive advantages. Cloud-based data management solutions help the industry meet its business and compliance challenges.
pharmaphorum
DECEMBER 15, 2022
Skin health-focused biopharma Almirall announced a CEO shakeup early in November, with Gianfranco Nazzi stepping down “to pursue new professional opportunities”. Bungay formerly served as CEO of Chroma Therapeutics and COO of Mereo Biopharma. Other biopharma hires. He will take over from interim CEO Sergio Marullo di Condojanni.
PharmExec
MARCH 13, 2023
Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal worth $1.7 billion, with Myovant being delisted from the New York Stock Exchange and its shares no longer publicly traded.
Pharma Leaders
MARCH 13, 2023
Following the completion of The post Sumitovant Biopharma completes acquisition of Myovant Sciences appeared first on Pharmaceutical Business review. The deal was announced on 23 October 2022. Sumitovant has acquired all outstanding shares of Myovant it did not own through the all-cash deal.
Pharmaceutical Technology
JANUARY 24, 2023
BioCryst Pharmaceuticals is collaborating with Swixx BioPharma for Orladeyo (berotralstat) commercialisation in Central and Eastern Europe (CEE). Under the deal, Swixx BioPharma will handle the commercialisation activities of oral therapy in 15 CEE markets.
Pharmaceutical Technology
JULY 29, 2022
As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. R&D ecosystem - Index score 6.54/10.
PharmaTech
MAY 17, 2023
Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.
Pharmaceutical Technology
JANUARY 20, 2023
Nevertheless, the potential for mAb therapies in treating medical conditions that have limited options means that biopharma companies are investing considerable resources in development. The post Overcoming challenges with scalability in biopharma manufacturing appeared first on Pharmaceutical Technology. Download to learn more.
Pharmaceutical Technology
SEPTEMBER 8, 2022
The post Roche to acquire biopharma firm Good Therapeutics for $250m appeared first on Pharmaceutical Technology. In August, the company entered a strategic partnership and licence agreement with Poseida Therapeutics for developing allogeneic CAR-T cell therapies for hematologic malignancies.
PharmaVoice
MAY 4, 2023
With leaders at the biggest biopharma companies bringing in millions, the CEO of Corvus Pharmaceuticals opted for a pay cut to pour more funds into science.
PharmaTech
AUGUST 2, 2022
Successful digital transformation in biopharma requires an integrated approach to the data lifecycle.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content